All Stories

  1. Effect of SGLT2 inhibitors on anemia and their possible clinical implications
  2. Efecto de los inhibidores del cotransportador sodio-glucosa tipo 2 sobre la anemia: posibles implicaciones clínicas
  3. Comparison of outcomes on hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) in anaemia associated with chronic kidney disease: network meta-analyses in dialysis and non-dialysis dependent populations
  4. The ERA Registry Annual Report 2021: a summary
  5. Unresolved aspects in the management of renal anemia, a Delphi consensus of the Anemia Group of the S.E.N
  6. Reticulocyte hemoglobin content and iron therapy in chronic kidney disease: Reply of the Anemia group of the Spanish Society of Nephrology
  7. Epidemiology and treatment of renal anaemia in Spain: RIKAS retrospective study
  8. Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist
  9. Opportunities to improve the management of anemia in peritoneal dialysis patients: lessons from a national study in routine clinical practice
  10. Agonistas del receptor de péptido similar al glucagón tipo 1 (GLP-1) en el manejo del paciente con diabetes mellitus tipo 2. Una aproximación para el nefrólogo
  11. Impacto pronóstico de la enfermedad renal crónica sobre el cierre percutáneo de la orejuela izquierda en la fibrilación auricular: una experiencia unicéntrica
  12. Trends in Mortality Due to Myocardial Infarction, Stroke, and Pulmonary Embolism in Patients Receiving Dialysis
  13. Incidence of severe breakthrough SARS-CoV-2 infections in vaccinated kidney transplant and haemodialysis patients
  14. Resistance to Erythropoiesis-Stimulating Agents among Patients on Hemodialysis Is Typically Transient
  15. Daprodustat for the Treatment of Anemia in Patients Not Undergoing Dialysis
  16. Iron Deficiency in CKD Without Concomitant Anemia
  17. Worldwide Early Impact of COVID-19 on Dialysis Patients and Staff and Lessons Learned: A DOPPS Roundtable Discussion
  18. Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference
  19. Aplastic crisis secondary to parvovirus B19 primoinfection as an infrequent cause of anemia in an immunocompetent, non-dialysis chronic kidney disease patient
  20. Medical Director Practice of Advising Increased Dietary Protein Intake in Hemodialysis Patients With Hyperphosphatemia: Associations With Mortality in the Dialysis Outcomes and Practice Patterns Study
  21. Anemia in Chronic Kidney Disease: From Pathophysiology and Current Treatments, to Future Agents
  22. Ferroterapia en el manejo de la anemia en la enfermedad renal crónica no en diálisis: perspectiva del grupo de anemia de la S.E.N
  23. Iron replacement therapy in the management of anaemia in non-dialysis Chronic kidney disease patients: Perspective of the Spanish Nephrology Society Anaemia Group
  24. Effect of comorbidities on survival in patients >80 years of age at onset of renal replacement therapy: data from the ERA-EDTA Registry
  25. Long- Versus Short-Acting Erythropoiesis-Stimulating Agent Type and Mortality
  26. SARS-CoV-2 Infection in a Spanish Cohort of CKD-5D Patients: Prevalence, Clinical Presentation, Outcomes, and De-Isolation Results
  27. Beta-2 microglobulin and all-cause mortality in the era of high-flux hemodialysis: results from the Dialysis Outcomes and Practice Patterns Study
  28. Apixaban Downregulates Endothelial Inflammatory and Prothrombotic Phenotype in an In Vitro Model of Endothelial Dysfunction in Uremia
  29. Endothelial Damage, Inflammation and Immunity in Chronic Kidney Disease
  30. Data from the ERA-EDTA Registry was examined for trends in excess mortality in European adults on kidney replacement therapy.
  31. Up‐regulation of HDACs, a harbinger of uraemic endothelial dysfunction, is prevented by defibrotide
  32. Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry
  33. Percutaneous Left Atrial Appendage Closure, A Safe Alternative To Anticoagulation For Patients With Non‐Valvular Atrial Fibrillation And End‐Stage Renal Disease On Hemodialysis: A Single Center Experience
  34. Sex Differences in Kidney Replacement Therapy Initiation and Maintenance
  35. Changes in clinical indicators related to the transition from dialysis to kidney transplantation—data from the ERA-EDTA Registry
  36. Vegetable-Based Diets for Chronic Kidney Disease? It Is Time to Reconsider
  37. Mortality due to bleeding, myocardial infarction and stroke in dialysis patients
  38. ¿Son seguros y eficaces los antiagregantes plaquetarios en los pacientes con insuficiencia renal?
  39. Changes in co-morbidity pattern in patients starting renal replacement therapy in Europe—data from the ERA-EDTA Registry
  40. Antioxidant and Anti-Inflammatory Strategies Based on the Potentiation of Glutathione Peroxidase Activity Prevent Endothelial Dysfunction in Chronic Kidney Disease
  41. Anemia of chronic kidney disease: Protocol of study, management and referral to Nephrology
  42. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología
  43. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología
  44. Anemia en la enfermedad renal crónica: protocolo de estudio, manejo y derivación a Nefrología
  45. Sodium zirconium cyclosilicate: a new potassium binder for the treatment of hyperkalemia
  46. Prolyl hydroxylase inhibitors for the treatment of anemia in chronic kidney disease
  47. Insuficiencia cardíaca en la enfermedad renal y déficit de hierro: importancia de la ferroterapia
  48. Heart failure in patients with kidney disease and iron deficiency: The role of iron therapy
  49. Serum osteoprotegerin in prevalent hemodialysis patients: associations with mortality, atherosclerosis and cardiac function
  50. TO021DIRECT FACTOR Xa INHIBITOR APIXABAN PREVENTS ENDOTHELIAL ACTIVATION AND DAMAGE ASSOCIATED WITH CHRONIC KIDNEY DISEASE
  51. Estimation of renal function by CKD-EPI versus MDRD in a cohort of HIV-infected patients: a cross-sectional analysis
  52. Gut microbiota in chronic kidney disease
  53. Enfermedad renal crónica y dislipidemia
  54. Microbiota intestinal en la enfermedad renal crónica
  55. Consensus on the Statin of Choice in Patients with Impaired Glucose Metabolism: Results of the DIANA Study
  56. Delphi consensus on the diagnosis and management of dyslipidaemia in chronic kidney disease patients: A post hoc analysis of the DIANA study
  57. Consenso Delphi sobre el diagnóstico y manejo de la dislipidemia en pacientes con enfermedad renal crónica: análisis post-hoc del estudio DIANA
  58. Factors influencing pathological ankle-brachial index values along the chronic kidney disease spectrum: the NEFRONA study
  59. Consenso Delphi sobre el manejo de la dislipidemia en pacientes con alteración del metabolismo de la glucosa: estudio Diana
  60. Estudio EPRICS con eritropoyetina: otro intento fallido para evitar el daño renal poscirugía cardiaca
  61. WITHDRAWN: Estudio EPRICS con eritropoyetina: otro intento fallido para evitar el daño renal poscirugía cardiaca
  62. Cinacalcet, Fibroblast Growth Factor-23, and Cardiovascular Disease in Hemodialysis
  63. Carotid Atherosclerotic Disease Predicts Cardiovascular Events in Hemodialysis Patients: A Prospective Study
  64. FO020ENDOTHELIAL DYSFUNCTION IN UREMIA: EFFECT OF FLAVONOIDS AND ANTIOXIDANTS
  65. Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease
  66. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1
  67. Clinical impact of the ERBP Working Group 2010 Recommendations for the anemia management in chronic kidney disease not on dialysis: ACERCA study1
  68. The Effects of Cinacalcet in Older and Younger Patients on Hemodialysis: The Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial
  69. TLR4 and NALP3 inflammasome in the development of endothelial dysfunction in uraemia
  70. Efficacy of a Simple Dosage Scheme to Convert From Shorter-acting Erythropoiesis-stimulating Agent to Continuous Erythropoietin Receptor Activator in Kidney Transplantation Patients
  71. Beneficial dose conversion after switching from higher doses of shorter-acting erythropoiesis-stimulating agents to C.E.R.A in CKD patients in clinical practice: MINERVA Study
  72. Sensitivity of Blood Volume Monitoring for Fluid Status Assessment in Hemodialysis Patients
  73. Evolution of the incidence of chronic kidney disease Stage 5 requiring renal replacement therapy in the diabetic population of Catalonia
  74. NFκB in the Development of Endothelial Activation and Damage in Uremia: An In Vitro Approach
  75. Relación del grado de control glucémico con las características de la diabetes y el tratamiento de la hiperglucemia en la diabetes tipo 2. Estudio DIABES
  76. Baseline characteristics of patients with chronic kidney disease stage 3 and stage 4 in spain: the MERENA observational cohort study
  77. Nocturnal, every-other-day, online haemodiafiltration: an effective therapeutic alternative
  78. Respuesta
  79. Prevalence of Chronic Kidney Disease in Patients With or at a High Risk of Cardiovascular Disease
  80. Prevalencia de insuficiencia renal crónica en pacientes de alto riesgo o con enfermedad cardiovascular
  81. Response
  82. What Infusion Flow Should Be Used for Mid-Dilution Hemodiafiltration?
  83. Introducción
  84. Abordaje multidisciplinar de la enfermedad aterotrombótica
  85. Conclusiones
  86. Mid-Dilution Hemodiafiltration: A Comparison with Pre- and Postdilution Modes Using the Same Polyphenylene Membrane
  87. Maintenance of target hemoglobin level in stable hemodialysis patients constitutes a theoretical task: a historical prospective study
  88. In Vivo Evaluation of Platelet Activation by Different Cellulosic Membranes
  89. Prevalence and Clinical Characteristics of HIV Type 1-Infected Patients Receiving Dialysis in Spain: Results of a Spanish Survey in 2006: GESIDA 48/05 Study
  90. Influence of the Ionic Dialysance Monitor on Kt Measurement in Hemodialysis
  91. Mspl identifies a biallelic polymorphism in the promoter region of the α2A-adrenergic receptor gene
  92. Differential Expression of Proteins From Cultured Endothelial Cells Exposed to Uremic Versus Normal Serum
  93. Chronic hypotension in hemodialysis patients: role of functional vascular changes and vasodilator agents
  94. Effect of Two Different Dialysis Membranes on Leukocyte Adhesion and Aggregation
  95. Dyslipidemia and the progression of renal disease in chronic renal failure patients
  96. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study
  97. Cigarette smoke concentrate increases 8-epi-PGF2$alpha; and TGF$beta;1 secretion in rat mesangial cells
  98. The effects of smoking and its cessation on 8-epi-PGF2α and transforming growth factor-beta 1 in Type 1 diabetes mellitus
  99. Biocompatibility of Cellulosic and Synthetic Membranes Assessed by Leukocyte Activation
  100. Update in nephrology: Highlights from the 36th Annual Meeting of the ASN
  101. Interactions Between Vasoconstrictors and Vasodilators in Regulating Hemodynamics of Distinct Vascular Beds
  102. Uraemic medium accelerates proliferation but does not induce apoptosis of endothelial cells in culture
  103. Darbepoetin alfa: A novel erythropoiesis-stimulating protein
  104. Nonconvulsive status epilepticus in dialysis patients
  105. Morbimortalidad cardiovascular en la diabetes mellitus tipo 2
  106. Análisis de la frecuencia cardíaca como factor de riesgo asociado a la progresión de la insuficiencia renal crónica
  107. Erythropoietin Triggers a Signaling Pathway in Endothelial Cells and Increases the Thrombogenicity of their Extracellular Matrices In Vitro
  108. Effect of angiotensin II receptor blockade on renal disease progression in patients with non‐diabetic chronic renal failure
  109. Hemodynamic and renal effects of acute and progressive nitric oxide synthesis inhibition in anesthetized dogs
  110. Hipermineralocorticismo exógeno como causa de descompensación de una hipertensión esencial previamente controlada
  111. Mecanismos de desarrollo del daño vascular en pacientes en diálisis
  112. Uremic Medium Disturbs the Hemostatic Balance of Cultured Human Endothelial Cells
  113. Increased plasma adrenomedullin levels in hemodialysis patients with sustained hypotension
  114. Abnormal platelet cytoskeletal assembly in hemodialyzed patients results in deficient tyrosine phosphorylation signaling
  115. Papel de la adrenomedulina en el control de la presión arterial y la homeostasis del líquido extracelular
  116. Doxazosin in a gastrointestinal therapeutic system formulation
  117. Novel Erythropoiesis Stimulating Protein
  118. Recombinant human erythropoietin treatment in chronic renal failure: Effects on hemostasis and vasculature
  119. β-adrenergic receptor density and function in left ventricular hypertrophy in young essential hypertensives
  120. Smoking increases serum levels of transforming growth factor-beta in diabetic patients
  121. Clinical pharmacology of nebivolol
  122. Erythropoietin Improves Signaling through Tyrosine Phosphorylation in Platelets from Uremic Patients
  123. Lamifiban
  124. Effect of recombinant human erythropoietin treatment on circulating reticulated platelets in uremic patients: Association with early improvement in platelet function
  125. Renal Failure in Multiple Myeloma
  126. Platelet-Leukocyte Activation during Hemodialysis Detected with a Monoclonal Antibody to Leukocyte Integrin CD11b
  127. Advances in hypertension management: Update 1998
  128. Autonomic nervous system and adrenergic receptors in chronic hypotensive haemodialysis patients
  129. New Insights Into the Pathophysiology of Renovascular Hypertension
  130. Vasoactive hormones in uraemic patients with chronic hypotension
  131. Correspondence
  132. Patients with multiple myeloma requiring long-term dialysis: presenting features, response to therapy, and outcome in a series of 20 cases
  133. Uraemic medium causes endothelial cell dysfunction characterized by an alteration of the properties of its subendothelial matrix
  134. Reticulated platelets in uremic patients: Effect of hemodialysis and continuous ambulatory peritoneal dialysis
  135. Effect of antihypertensive treatment on the increased β-adrenoceptor density in patients with essential hypertension
  136. Reversible Decrease of Surface ß2-Adrenoceptor Number and Response in Lymphocytes of Patients with Pheochromocytoma
  137. 24 Effect of antihypertensive treatment on increased (??2-adrenoceptor density in patients with essential hypertension
  138. 31 Decreased ??2-adrenoceptor number and responsiveness in patients with phaeochromocytoma
  139. Intracellular calcium mobilization and activation of the Na+/H+exchanger in platelets
  140. Minimal-Change Glomerulopathy and Carcinoma
  141. Recombinant human erythropoietin treatment improves platelet function in uremic patients
  142. Calciphylaxis in a Hemodialysis Patient: Appearance After Parathyroidectomy During a Psoriatic Flare
  143. Lymphocyte surface beta2-adrenoceptors in essential hypertension
  144. Lymphocyte surface beta2-adrenoceptors in essential hypertension
  145. Tumor Markers in Chronic Renal Failure and Hemodialysis Patients
  146. Ocular and Auditory Toxicity in Hemodialyzed Patients Receiving Desferrioxamine
  147. Lymphocyte β2-Adrenergic Receptors in Essential Hypertension: Studies in Basal Conditions and After Dynamic Exercise
  148. Treatment of Hyperkalaemia in Renal Failure: Salbutamol v. Insulin
  149. Improvement of renal function in azotaemic hypertensive patients after surgical revascularization
  150. Reversal of Renal Failure after Revascularization in Atheromatous Renovascular Disease
  151. A Possible Pathogenic Mechanism for Rhabdomyolysis Associated with Multiple Myeloma
  152. Visceral Involvement of Dialysis Amyloidosis
  153. Rhabdomyolysis Associated With Pleural Tuberculosis
  154. NIFEDIPINE-INDUCED PAROTITIS